Key facts
- An experimental peptide, BPC-157, is being used for a wide range of ailments despite little safety and efficacy evidence from human studies.
- BPC-157 has not been approved for use in the United States but has attracted consumers in a gray market.
- The number of new confirmed users of BPC-157 increased 33-fold between 2020 and 2026.
- Reasons for use were documented in 644 patients, who took the compound for conditions ranging from sports injuries and chronic pain to gastrointestinal disorders.
- When patients discontinued BPC-157, it was most often because their doctors advised them to stop or due to adverse effects.
An experimental peptide known as BPC-157, which is being promoted online for its potential benefits in pain relief, healing, and performance enhancement, is seeing increased use despite a lack of robust safety and efficacy data from human studies, according to a new analysis. The peptide, often combined with TB-500 in a combination called the "Wolverine stack," has not received approval from the U.S. Food and Drug Administration (FDA).
In July, an FDA advisory panel voted to permit the compounding of BPC-157 by pharmacies, a move encouraged by U.S. Health Secretary Robert F. Kennedy Jr. Previously, the FDA had imposed restrictions on its compounding due to concerns about significant safety risks and insufficient human data. Analysts estimate that BPC-157 and similar peptides could represent a market worth $2 billion to $3 billion if they were to be legitimized.
The analysis, conducted by data analytics firm nference, reviewed over 15 million medical records and identified 1,039 patients whose doctors had manually documented the use of BPC-157 in clinical notes. The study leader, Venky Soundararajan, stated that the actual scale of the peptide's use is likely unknown, as most doctors may not be inquiring about their patients' use of it.
Researchers found that the number of new confirmed users of BPC-157 surged 33-fold between 2020 and 2026. For 644 patients with documented reasons for use, the unapproved compound was taken for conditions including sports injuries, chronic pain, and gastrointestinal disorders. It was most frequently initiated to manage pain or gastrointestinal symptoms and was typically obtained from compounding pharmacies or gray-market vendors.
The demographic of users shifted between 2020 and 2026, with the proportion of males increasing from 57% to 70%, and the average age decreasing from 55 to 49. Among the 972 users with recorded race, 96% were white. Treatment responses were documented for only about one-third of patients, with some notes indicating symptom improvement. However, the limited data highlighted uncertainty regarding the peptide's effects and underscored a lack of comprehensive data on its safety and effectiveness, according to the report published ahead of peer review.
Discontinuation of BPC-157 was often prompted by physician advice or due to adverse effects, including neuropsychiatric, dermatologic, and gastrointestinal symptoms. Dr. Flynn McGuire of the University of Utah, who has researched BPC-157, noted that about half of the documented users were also taking other medications or undergoing interventions like physical therapy and surgery. He emphasized that without a placebo or untreated comparator group, and with variations in indications, formulations, doses, and treatment durations, it is impossible to attribute improvements solely to BPC-157 versus natural recovery, other treatments, or placebo effects. McGuire and the paper's authors concluded that randomized controlled trials are necessary to determine if BPC-157 offers clinically meaningful improvements.